Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC

This study has been withdrawn prior to enrollment.
(The progress of enrollment is too slow.)
Information provided by (Responsible Party):
Xichun Hu, Fudan University Identifier:
First received: May 9, 2014
Last updated: December 24, 2015
Last verified: December 2015
This research is designed to investigate whether the addition of fulvestrant 500mg to anastrozole is better than anastrozole alone as first-line endocrine therapy for advanced breast cancer.

Condition Intervention Phase
Carcinoma Breast Stage IV
Drug: Fulvestrant
Drug: Anastrozole
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Multi-center, Randomized Phase II Study of Fulvestrant Anastrozole Combination Versus Anastrozole Alone in Patients With Luminal A-like Postmenopausal Advanced Breast Cancer

Resource links provided by NLM:

Further study details as provided by Fudan University:

Primary Outcome Measures:
  • PFS(Progression free survival) [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • OS(overall survival ) [ Time Frame: 8 weeks ]

Other Outcome Measures:
  • ORR(objective response rate) [ Time Frame: 8 weeks ]
  • CBR(Clinical benefit rate) [ Time Frame: 8 weeks ]
  • Number of patients with grade 3 or 4 adverse events [ Time Frame: 8 weeks ]

Enrollment: 0
Study Start Date: March 2014
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fulvestrant and anastrozole
Anastrozole 1 mg PO QD Fulvestrant 500mg IM d1,15, 29 and 4 weeks after
Drug: Fulvestrant
Adding fulvestrant to the standard endocrine therapy, anastrozole
Other Name: falsodex
Drug: Anastrozole
standard endocrine therapy
Other Name: Arimidex
Active Comparator: Anastrozole
Anastrozole 1 mg PO QD
Drug: Anastrozole
standard endocrine therapy
Other Name: Arimidex

Detailed Description:
Anastrozole is the standard first-line endocrine treatment for patients with hormonal receptor positive advanced breast cancer. It has been proven that the addition of fulvestrant 250mg can enhance PFS of anastrozole monotherapy according to SWOG0226 study. However, the optimal recommended dose of fulvestrant for patients with advanced breast cancer is 500mg worldwide according to CONFIRM study. The investigator designed this research to investigate whether high dose fulvestrant can further improve efficacy of anastrozole monotherapy.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed informed consent
  2. Histologically confirmed breast cancer
  3. Luminal A-like breast cancer (primary or metastatic tumor), defined as: ER-positive, PR-positive (> 20%), Her-2 negative and Ki67 <14%.
  4. Advanced breast cancer is eligible:

    • Endocrine therapy-naive patients with locally advanced disease, who are not suitable for radical surgery or radiotherapy (the decision made by the multidisciplinary breast cancer team). Prior first-line cytotoxic chemotherapy is acceptable. or
    • Patients with recurrent or metastatic disease, who have not received adjuvant endocrine therapy or who have been 2 years or longer after stop of adjuvant endocrine therapy. Patients who had disease progression from first-line cytotoxic chemotherapy are allowed.
  5. At least one lesion (measurable and / or non-measurable) can be assessed at baseline, and is suitable for repeated assessments with CT and/or MRI.
  6. Postmenopausal women, defined as any one of the following criteria (as defined in the NCCN's menopause definition):

    • previous bilateral oophorectomy
    • 60 years old or older
    • less than 60 years old, amenorrheic for 12 months or longer in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and follicle-stimulating hormone and estradiol in the postmenopausal range.
    • If taking tamoxifen, or toremifene and age < 60, then FSH and E in the postmenopausal range
  7. ECOG 0, 1 or 2.
  8. Patients with good compliance.
  9. Must be able to swallow tablets.
  10. Without any significant gastrointestinal obstruction or dysfunction of absorption for oral drug.

Exclusion Criteria:

  1. Life-threatening metastatic visceral disease, defined as extensive liver involvement or any degree of brain or leptomeningeal involvement (past or present) or symptomatic pulmonary lymphatic metastasis. If the investigator believe that their respiratory function is not significantly impaired due to illness, patients with scattered parenchymal metastases are qualified.
  2. Have received any systemic treatment other than first-line cytotoxic chemotherapy.
  3. Radiation therapy within 28 days prior to randomization (exception: radiotherapy to control bone pain, but should be completed before the randomization).
  4. Use any other anti-cancer therapy at the same time (except bisphosphonate).
  5. Previous endocrine treatment for advanced breast cancer.
  6. Current or previous malignancy ( except for breast cancer, basal cell or squamous cell carcinoma of the skin with adequate treatment, cervical carcinoma in situ).
  7. Inadequate blood or liver or renal function within one week prior to randomization: Platelets < 80 × 10^9/L; Total bilirubin > 1.5 × (ULRR) (patients with Gilbert's syndrome is eligible); or ALT or AST > 2.5 × ULRR (without liver metastases) or > 5 × ULRR (with liver metastases).
  8. History with hemorrhagic constitution (e.g. disseminated intravascular coagulation, clotting factor deficiency) or long-term anticoagulant therapy.
  9. Hypersensitivity history to excipients or castor oil of fulvestrant or anastrozole.
  10. Any other severe co-existing medical disorders, ie uncontrolled heart disease.
  11. Participation in any clinical trial and / or exposure to any investigational medication within 28 days before randomization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02140437

Sponsors and Collaborators
Fudan University
Principal Investigator: Xichun Hu, MD.PhD. Fudan University
  More Information

Responsible Party: Xichun Hu, M.D. Ph. D., Fudan University Identifier: NCT02140437     History of Changes
Other Study ID Numbers: Fudan BR2014-14
Study First Received: May 9, 2014
Last Updated: December 24, 2015

Keywords provided by Fudan University:
Luminal A-like
Advanced breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypnotics and Sedatives
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
GABA Modulators
GABA Agents processed this record on April 24, 2017